Orris

chronic RA treatment

Reading File
Reading File
Reading File
Reading File
Searching the Web

2025 rheumatoid arthritis treatment guideline chronic management EULAR ACR

Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"rheumatoid arthritis"[MeSH Terms] AND treatment

Reading File
Reading File
Finding Sources
Searching the Web

EULAR recommendations management rheumatoid arthritis synthetic biologic DMARD 2025 update full text

Finding Sources
Finding Sources

Chronic rheumatoid arthritis (RA) treatment

The goal is remission or low disease activity, using a treat-to-target approach with regular assessment and timely adjustment. Disease-modifying treatment should control inflammation to prevent joint damage, disability, and systemic complications. Firestein & Kelley's Textbook of Rheumatology, p. 1523.

1. Core long-term medicines: DMARDs

These slow or stop joint damage, unlike simple pain medicines.
  • Methotrexate (MTX) is usually first choice, often with folic acid. It is commonly the anchor drug for combination treatment.
  • If MTX is unsuitable or not tolerated: leflunomide, sulfasalazine, or hydroxychloroquine may be used.
  • Hydroxychloroquine requires retinal monitoring. MTX and leflunomide require blood-count, liver, and renal monitoring. Harrison's Principles of Internal Medicine, 22e, p. 2893.

2. If RA remains active despite conventional DMARDs

A rheumatologist usually adds or switches to an advanced DMARD, commonly with MTX:
GroupExamples
TNF inhibitorsadalimumab, etanercept, infliximab, certolizumab, golimumab
Non-TNF biologicsabatacept, tocilizumab, sarilumab, rituximab
JAK inhibitorstofacitinib, baricitinib, upadacitinib, filgotinib where available
Choice depends on prior treatment response, infections, tuberculosis or hepatitis risk, cardiovascular and clotting risk, cancer history, lung disease, pregnancy plans, route preference, and cost/access.
JAK inhibitors require particular risk assessment in people with older age, smoking history, cardiovascular disease, prior blood clots, or malignancy risk. The recent EULAR RA DMARD update incorporates newer evidence in this area.

3. Steroids and pain relief

  • Glucocorticoids such as prednisone can be used briefly as a bridge while DMARDs take effect, then tapered off. Long-term maintenance steroids should generally be avoided because of osteoporosis, diabetes, infection, cataracts, hypertension, and cardiovascular harm. Firestein & Kelley's Textbook of Rheumatology, p. 1523.
  • NSAIDs can help pain and stiffness but do not prevent erosions or disease progression. Use the lowest effective dose for the shortest time, considering gastrointestinal, kidney, blood-pressure, and cardiovascular risks.
  • Acetaminophen, topical NSAIDs, injections for a single troublesome joint, and short courses of other analgesia may sometimes support symptom control, but they do not replace DMARD treatment.

4. Monitoring and prevention

Before biologic or JAK therapy, clinicians commonly assess for:
  • Tuberculosis and hepatitis B/C
  • Vaccination status, ideally updating non-live vaccines before immunosuppression
  • Baseline CBC, liver enzymes, kidney function, and disease activity score
  • Pregnancy intentions and medication safety
During treatment, monitor disease activity and medication toxicity. If the target is not met, therapy should be adjusted rather than continuing ineffective treatment for months.

5. Non-drug treatment

  • Regular low-impact aerobic and strengthening exercise
  • Physiotherapy and occupational therapy
  • Smoking cessation
  • Healthy weight, sleep, and cardiovascular risk management
  • Bone protection if steroid exposure or osteoporosis risk is present
  • Hand/foot supports or orthopedic input if there is persistent functional damage

6. When medication reduction is considered

Only consider tapering after sustained, stable remission or low disease activity, and usually continue at least one DMARD. Stopping all therapy has a significant flare risk. Firestein & Kelley's Textbook of Rheumatology, p. 1523.
Bottom line: chronic RA is usually managed with MTX-based treat-to-target therapy, escalation to a biologic or JAK inhibitor when needed, minimal steroid exposure, and ongoing safety monitoring with a rheumatologist.
Recent systematic reviews in 2024-25 support current individualized DMARD-based management, without overturning this framework: PMIDs 39939220, 41357870, and 38979406.
This is a shared conversation. Sign in to Orris to start your own chat.